Technical datasheet
Description
The monoclonal antibody 55R-170 recognizes the extracellular part of mouse Tumor Necrosis Factor Receptor superfamily member 1A (TNF-RI), also known as CD120a or p55. TNF-RI belongs to the large TNF receptor family, among which TNF-RII (TNF-R p75-80), lymphotoxin-beta receptor (LTbetaR) and the Herpes virus entry mediator (HVEM). Ligands for these receptors belong to the Tumor Necrosis Factor (TNF) superfamily of cytokines, which activate signaling pathways for cell survival, death, and differentiation that orchestrate the development, organization and homeostasis of lymphoid, mammary, neuronal and ectodermal tissues.
TNF-RI contains a characteristic structural cassette termed death domain in its sequence that is conserved within a distinct subset of other TNF-R family members, such as CD95, DR3, DR4, and DR5. This death domain, was characterized as being essential for induction of apoptosis in vitro and has been structurally conserved within these TNF-R superfamily members. Deletion of the death domain of the TNF-RI results in a non-functional receptor, indicating that the death domain is required for the signal transduction of the physiological functions of TNF-RI in vivo.
TNF-RI is a 55 kD type I transmembrane protein and is expressed on a variety of cell types at low levels. It is considered to play a prominent role in cell stimulation by TNF-alpha. Induction of cytotoxicity and other functions are mediated largely via TNF-RI. TNF-RI is present as soluble form in body fluids (for instance plasma and CSF). This extracellular TNF-RI is generated by two mechanisms, namely proteolytic cleavage of TNF-RI ectodomains and release of full-length TNF-RI in the membranes of exosome-like vesicles. TNF-RI and TNF-RII both interact with the homomeric forms of LTbeta or TNF. However, TNF-RI functions as the high affinity receptor for soluble TNF (sTNF). TNF-RI has been shown to be involved in a wide variety of inflammatory diseases, among which neurodegenerative diseases (Parkinson’s and Alzheimer’s disease), multiple sclerosis, asthma, atherosclerosis, rheumatology.
The monoclonal antibody 55R-170 also recognizes the soluble receptor.
Immunogen
Purified soluble extracellular domain of mouse TNF-RI
Formulation
1 ml (100 µg/ml) 0.2 µm filtered FITC conjugated antibody solution in PBS, containing 1% bovine serum albumin.
Species
Armenian hamster IgG
Application
|
|
F
|
FC
|
FS
|
IA
|
IF
|
IP
|
P
|
W
|
|
Yes
|
|
●
|
●*
|
●
|
|
●
|
|
|
|
No
|
|
|
|
|
|
|
|
|
|
N.D.
|
●
|
|
|
|
●
|
|
●
|
|
* The monoclonal antibody 55R-170 is an antagonistic antibody useful for blocking of TNR-RI both in vitro and in vivo.
N.D.= Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Fluorescence; IP = Immuno Precipitation; P = Paraffin sections; W = Western blot
Use
For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Aliases
TNFR type I, CD120a, TNF-RI, TNF-R55, TNFRp55, p55-R, TNF receptor alpha chain
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.
References
- Sheehan, K et al; Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995, 181: 607
- Pinckard, J et al; Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997, 272: 10784
- Ji, H et al; Critical roles for interleuking 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002, 196: 77
- Lee, S et al; Inhibition of TCR-induced CD8 T cell death by IL-12: regulation of Fas ligand and cellular FLIP expression and caspase activation by IL-12. J Immunol 2003, 170: 2456
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Also available